Building confidence in ibuprofen safety amidst the uncertainty of the COVID-19 pandemic
Building confidence in ibuprofen safety amidst the uncertainty of the COVID-19 pandemic
3 PagesAt the onset of COVID-19, concerns arose that ibuprofen could worsen outcomes, creating uncertainty for clinicians and patients. IQVIA rapidly applied OMOP tools to design a comparative effectiveness study using U.S. claims databases covering over 10 million patients. Propensity score matching and Cox hazard models compared ibuprofen users to those taking NSAIDs, COX-2 inhibitors, or paracetamol. Results showed no increased risk of COVID-19 infection or hospitalization with ibuprofen, consistent before and during the pandemic. Findings were published in Drugs with Oxford, supported by a public dashboard, providing reassurance on ibuprofen safety.
